Xi`an Eastling Biotech Co., Ltd.
Diamond Supplier
- Diamond
Supplier - 1st
years
Diamond Supplier
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Lab/Research institutions
Tel: +86-156-91766041
Mobile:
Tel: +86-156-91766041
Fax:
URL: http://www.eastlingbiotech.com/
Province/state: Shaanxi
City: Xi'an city
Street: No. 201, Unit 4, Building 9, Hongqi Community, Tanjia Street, Weiyang District, Xi 'an, Shaanxi
MaxCard:
Contact Suppliers
CAS NO.19237-84-4
98%(500-1000)Kilogram98%(100-500)Metric Ton
prazosin hydrochloride
CAS: 19237-84-4
Molecular Formula: C19H22ClN5O4
| Name | prazosin hydrochloride |
| Synonyms | Prazosin HCl Prazosin hydrochlori prazosin hydrochloride Prazosin Hydrochloride (500 mg) 4-Amino-2-pyroyl-6,7-dimetoxypiperazin-1-yl-chynazolina hydrochloride 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazinehydr [4-(4-AMino-6,7-diMethoxy-2-quinazolinyl)-1-piperazinyl]-2-furanylMethanone Hydrochloride [4-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone hydrochloride Furazosin hydrochloride, 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine hydrochloride Prazosin hydrochloride,1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine hydrochloride, Furazosin hydrochloride |
| CAS | 19237-84-4 |
| EINECS | 242-903-4 |
| InChI | InChI=1/C19H21N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22);1H |
| InChIKey | WFXFYZULCQKPIP-UHFFFAOYSA-N |
| Molecular Formula | C19H22ClN5O4 |
| Molar Mass | 419.86 |
| Melting Point | 277 - 280°C |
| Boling Point | 638.4°C at 760 mmHg |
| Flash Point | 339.9°C |
| Water Solubility | Soluble in dimethyl sulfoxide, ethanol, water, methanol. |
| Solubility | Soluble in dimethyl sulfoxide, ethanol, water, methanol. |
| Vapor Presure | 3.4E-16mmHg at 25°C |
| Appearance | off-white to yellow powder |
| Color | white |
| Merck | 14,7717 |
| BRN | 4303561 |
| Storage Condition | 2-8°C |
| MDL | MFCD00058177 |
| Physical and Chemical Properties | Appearance: white or white crystalline powder moisture: less than or equal to 2.0% (anhydrous prazosin),<8-15% (hydrous prazosin) ignition residue: less than or equal to 0.4% heavy metals: ≤ 50ppm related substances: in accordance with the provisions of the content: according to the anhydrous C19H21N5O4HCL, not less than 99.0%, not more than 102.0 |
| Use | Used as an antihypertensive agent |
| Hazard Symbols | Xn - Harmful |
| Risk Codes | R22 - Harmful if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. R62 - Possible risk of impaired fertility |
| Safety Description | S28 - After contact with skin, wash immediately with plenty of soap-suds. S36 - Wear suitable protective clothing. |
| UN IDs | 3249 |
| WGK Germany | 3 |
| RTECS | VA1350000 |
| FLUKA BRAND F CODES | 10 |
| HS Code | 2934990002 |
| Hazard Class | 6.1(b) |
| Packing Group | III |
| Overview | Prazosin hydrochloride (P razosin Hydrochloride) is a blocker that selectively acts on postsynaptic αl adrenergic receptors in blood vessels and nerves. It is a quinazoline derivative that can relax vascular smooth muscle, expand peripheral blood vessels, reduce peripheral blood vessel resistance, lower blood pressure, has no effect on presynaptic membrane α2 receptors, but can block postsynaptic membrane α1, anti-norepinephrine, new forlin and epinephrine boost response. Clinically, it is mainly used to treat various degrees of hypertension, chronic congestive heart failure and prostatic hyperplasia. The biggest advantage of prazosin hydrochloride is that it has no obvious adverse effect on metabolism, and has a good effect on blood lipid metabolism. It is especially effective for hypertensive patients with diabetes or renal insufficiency. Compared with other antihypertensive drugs, it has the following advantages: 1. Compared with other vasodilators, such as hydralazine, it rarely causes tachycardia and does not increase renin secretion; 2. It is different from clonidine, methyldopa and other antihypertensive drugs. It has no central nervous system effect and will not cause side effects such as depression, impotence, and loss of libido; 3. Prazosin does not affect renal function, no effect on renal blood flow and glomerular filtration rate. Studies have shown that a single dose of prazosin can effectively treat hypertension. When other antihypertensive drugs are used and the effect is not good or the dose cannot be increased due to side effects, the addition of prazosin can improve blood pressure. effect. There are no significant changes in renal function in hypertensive patients with long-term prazosin. In hypertension with renal insufficiency, many antihypertensive drugs can reduce renal blood flow and increase nitrogen retention. However, prazosin will not affect renal blood flow and can reduce nitrogen retention in the process of lowering blood pressure. This is an ideal antihypertensive drug for hypertension with renal insufficiency. In addition, prazosin also has certain application and effect in the treatment of refractory heart failure. Prazosin can selectively expand resistance blood vessels and volume blood vessels. It can expand both arterial blood vessels and venous blood vessels. It can reduce the front and back load of the heart of patients with severe heart failure in a balanced manner and improve the heart pumping function. It is worthy of clinical promotion. Fig. 1 is the structural formula of prazosin hydrochloride |
| pharmacological effects | this product is a selective postsynaptic α1 adrenergic receptor blocker. It can dilate the surrounding blood vessels and reduce the vascular resistance and cause the blood pressure to drop. It does not block presynaptic membrane α2 receptors, has no obvious effect on heart rate and cardiac output, and does not increase renin secretion. This medicine can dilate arteries and veins, reduce the load before and after the heart, reduce the end diastolic pressure of the left ventricle, and improve the heart function, so it can be used for heart failure. |
| terazosin hydrochloride | terazosin hydrochloride is mainly used to treat mild or moderate hypertension, reducing blood pressure by reducing total peripheral vascular resistance. The vasodilation and blood pressure lowering effects of terazosin seem to be mainly caused by a1-adrenergic receptor blockade. It can be administered alone or in combination with other antihypertensive drugs such as thiazide diuretics or β-blockers. It can also be used for the treatment of symptoms of urinary retention caused by benign prostatic hyperplasia (BPH). Male patients are basically completely absorbed after taking medicine. The effect of taking medicine immediately after a meal on the degree of absorption is minimal, but the time to peak plasma concentration is delayed by about 40 minutes. The hepatic first pass metabolism of terazosin is very small. The peak is reached about 1 hour after taking the drug, and the half-life is about 12 hours. In the study of the effect of age on the pharmacokinetics of terazosin, it was found that the plasma half-lives of patients aged 70 and 20 to 39 years old were 14.0 and 11.4 hours respectively. The plasma protein binding rate was 90% ~ 94%. About 40% is excreted in urine and about 60% is excreted in feces. In clinical trials, the proportion of patients treated with this product and angiotensin (ACE) inhibitors and diuretics reported vertigo or other related adverse reactions was higher than that of all patients treated with this product. When this product is combined with other antihypertensive drugs, attention should be paid to observe to avoid significant hypotension. When this product is added to diuretics or other antihypertensive drugs, the dose should be reduced and reformulated if necessary. It is known that this product will not interact with analgesics/anti-inflammatory drugs, cardiac glycosides, hypoglycemic drugs, antiarrhythmic drugs, antianxiety drugs/sedatives, antibacterial drugs, hormones/steroids and gout drugs. Overdose of this product may cause acute hypotension. Cardiovascular support therapy should be used in this method. Patients should lie on their backs to restore blood pressure and normalize heart rate. If this method cannot be solved, the volume should be expanded first to treat shock, and vasopressors should be used if necessary. Renal function should be monitored and routine supportive therapy should be applied. Because this product has a high plasma protein binding rate, dialysis is ineffective. |
| pharmacokinetics | oral absorption is complete, bioavailability is 50% ~ 85%. The plasma protein binding rate was 97%. It took effect 30 min after oral administration, reached a peak of 1~2h, and lasted for 10h. The best time for the combination is after 3 to 4 weeks. The drug is metabolized in the liver, and the main metabolites are excreted through bile and feces. A small amount (6% ~ 10%) is excreted from the kidney. The drug cannot be removed by dialysis. |
| use | suitable for mild to moderate hypertension, combined with beta blockers or diuretics, the antihypertensive effect is better. As a second-line drug, it is often used or combined when the first-line drug treatment is not satisfactory; it is used to treat moderate and severe chronic congestive heart failure and heart failure after myocardial infarction, and it is also effective for refractory heart failure. Can be used to treat ergotamine overdose. (2016-6-16) Used as an antihypertensive drug |
Mol Download Chemical properties
CAS:
19237-84-4
MF:
C19H22ClN5O4
MW:
419.86
EINECS:
242-903-4
MDL No.:
MFCD00058177
Melting point:
277 - 280 °C
storage temp.
2-8°C
solubility
H2O: 1 mg/mL, clear, colorless
form
solid
color
white
Water Solubility
Soluble in dimethyl sulfoxide, ethanol, water, methanol.
Merck
14,7717
BRN
4303561
InChIKey
WFXFYZULCQKPIP-UHFFFAOYSA-N
Xi'an Eastling biotech Co., Ltd. is dedicated to the research and development, production, and sales of natural plant extracts; With nearly 15 years of experience in identifying, researching, developing, and producing active ingredients for medicinal plants, we focus on providing innovative products and services to customers in industries such as pharmaceuticals, health food, and cosmetics.
Eastling Biotechnology has established a global direct harvesting system for plant raw materials, ensuring the high quality and authenticity of raw materials, while also protecting the continuity and diversity of plants; Having strong research and development capabilities, we can develop more effective and specialized plant active ingredients for the pharmaceutical, health food, and cosmetics industries; We have established an advanced quality control system, and the quality control of our products depends on advanced testing instruments and high-level technical experts. The effective combination of the two forms Eastling's ability to quickly and rigorously control product quality.
We have a production system that complies with Chinese GMP and American cGMP certifications, as well as advanced and optimized large-scale industrial production technology. In addition to producing specific products for Eastling Biotechnology, we also provide customized services to meet the characteristics and needs of different customers to produce customized products.
We believe that natural active ingredients are the foundation of our service to customers. Scientific and effective production technology is the foundation for us to provide customers with specialized products. We have the ability to serve customers in the pharmaceutical, health food, and cosmetics industries, provide new product solutions, and add new value to their products.